Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Nuwellis Inc (NUWE) Price & Performance

iShares S&P GSCI Commodity-Indexed Trust ETFTrade
Nuwellis IncTrade

Price performance (Past 24H)

Key statistics

iShares S&P GSCI Commodity-Indexed Trust ETF vs Nuwellis Inc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $31.06, while Nuwellis Inc trades at $2.93 (market cap $1.10M). The key difference: iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.

GSGNUWE
Sector
Commodities - Metals/AgricultureTechnology
52-Week High
$34.77$558.26
52-Week Low
$22.06$2.80
Market Cap
$1.10M
Enterprise Value
-$709.83K

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares S&P GSCI Commodity-Indexed Trust ETF

GSG trades at $31.00, up 1.57% today, with strong bullish technical signals from moving averages and ADX indicators, though RSI levels suggest overbought conditions. The stock's support and resistance levels are consolidated at $31.00, indicating a pivotal price point. Recent news highlights commodities as a key market theme, which may benefit GSG given its focus.

The outlook for GSG is cautiously optimistic, driven by bullish technical trends and positive sentiment around commodities. Risks include potential overbought corrections and reliance on commodity market stability. Investment opportunities hinge on sustained commodity demand, but investors should monitor earnings fundamentals for validation.

Nuwellis Inc

Nuwellis (NUWE) trades at $3.22, up 15% in the last 24 hours, following a recent 35:1 reverse stock split executed on June 26, 2026. The medical technology company shows a mixed financial picture with a strong gross margin of 65.47% but significant net losses and negative profitability ratios. Recent news highlights expansion in pediatric care, new patent awards, and a $6 million public offering closed in June 2026 to fund operations. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure.

The outlook remains challenging due to persistent operating losses and negative cash flow, offset by strategic pediatric market expansion and new product innovation. Investment opportunity hinges on the company's ability to translate its high gross margin and recent capital raise into sustainable revenue growth and eventual profitability. Key risks include continued cash burn, execution of commercial strategy, and reliance on financing activities to fund operations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares S&P GSCI Commodity-Indexed Trust ETF

GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.

Read more on GSG

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE